3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
55
Neoplasms
15
Sarcoma
12
Neoplasm Metastasis
8
Carcinoma, Non-Small-Cell Lung
6
Triple Negative Breast Neoplasms
5
Unspecified Adult Solid Tumor, Protocol Specific
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Liposarcoma
2
Leiomyosarcoma
2
Carcinoma
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Salivary Gland Neoplasms
1
Relapsed Solid Tumors
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neurotoxicity Syndromes
1
Neoplastic Cells, Circulating
1
Neoplasm, Residual
1
Lymphoma
1
Interventions
Trabectedin
2
Doxorubicin
2
Dacarbazine
2
pazopanib
1
eribulin
1
Sunitinib
1
Nivolumab
1
Methotrexate
1
Ifosfamide
1
Epirubicin
1
Dasatinib
1
Cisplatin
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Solitary Fibrous Tumors
×
eribulin
×
Clear all
NCT03840772
2024-09-20
ERASING
Italian Sarcoma Group
Phase 2
Completed
16 enrolled